Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 1. Animal instincts. Animal instincts. Half-horse, half-human, the mythological centaur Chiron (root, chirourgos: surgeon) taught all of the great.

Published bySteven Williamson Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 1. Animal instincts. Animal instincts. Half-horse, half-human, the mythological centaur Chiron (root, chirourgos: surgeon) taught all of the great."— Presentation transcript:

1 Fig. 1. Animal instincts. Animal instincts. Half-horse, half-human, the mythological centaur Chiron (root, chirourgos: surgeon) taught all of the great heroes with skills related to human health (Jason, Peleus, Asklepios, and Achilles). Following in this tradition, most animal studies are performed to gain insights into human physiology, pathophysiology, and response to new therapies. Unfortunately, many other centaurs (like the female centaur shown here) were more biased and profligate. John P. A. Ioannidis Sci Transl Med 2012;4:151ps15 Copyright © 2012, American Association for the Advancement of Science

Download ppt "Fig. 1. Animal instincts. Animal instincts. Half-horse, half-human, the mythological centaur Chiron (root, chirourgos: surgeon) taught all of the great."

Similar presentations

Deep Sequencing of Patient Genomes for Disease Diagnosis: When Will It Become Routine? by Stephen F. Kingsmore, and Carol J. Saunders Sci Transl Med Volume.

Deep Sequencing of Patient Genomes for Disease Diagnosis: When Will It Become Routine? by Stephen F. Kingsmore, and Carol J. Saunders Sci Transl Med Volume.
Fig. 1. Animal instincts. Animal instincts. Half-horse, half-human, the mythological centaur Chiron (root, chirourgos: surgeon) taught all of the great.

Fig. 1. Animal instincts. Animal instincts. Half-horse, half-human, the mythological centaur Chiron (root, chirourgos: surgeon) taught all of the great.
Fig. 6. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections.

Fig. 6. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections.
Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.
Fig. 7 Correlation of NHP and human ISGs.

Fig. 7 Correlation of NHP and human ISGs.
Fig. 1 Movement percepts for all participants.

Fig. 1 Movement percepts for all participants.
Consolidated Standards of Reporting Trials flow diagram of VRC trial

Consolidated Standards of Reporting Trials flow diagram of VRC trial
Fig. 2 Whisker deprivation accelerates and enhances behavioral recovery after right S1FP photothrombosis. Whisker deprivation accelerates and enhances.

Fig. 2 Whisker deprivation accelerates and enhances behavioral recovery after right S1FP photothrombosis. Whisker deprivation accelerates and enhances.
Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.
Filipin staining of marginal gyrus of cerebral cortex in NPC cats

Filipin staining of marginal gyrus of cerebral cortex in NPC cats
Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.

Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.
Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.
Fig. 1. MSCs undergo in vivo apoptosis after infusion without affecting immunosuppression. MSCs undergo in vivo apoptosis after infusion without affecting.

Fig. 1. MSCs undergo in vivo apoptosis after infusion without affecting immunosuppression. MSCs undergo in vivo apoptosis after infusion without affecting.
Fig. 3. Comparison of prediction performance.

Fig. 3. Comparison of prediction performance.
Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.
Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.
Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.
Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.
Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.
Fig. 1. Value proposition. Value proposition.Summarized are the valuation estimates (log scale), from panel members (selected by A.W.L.) for the NCATS.

Fig. 1. Value proposition. Value proposition.Summarized are the valuation estimates (log scale), from panel members (selected by A.W.L.) for the NCATS.

Similar presentations

Ads by Google